Epizyme reported $370K in Interest Expense on Debt for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Interest Expense On Debt Change
Abbott ABT:US $ 131M 0M
Amgen AMGN:US $ 295M 40M
Avrobio Inc AVRO:US 304K 101K
Biogen BIIB:US $ 66.1M 0.2M
Epizyme EPZM:US $ 370K 0
Gilead Sciences GILD:US $ 238M 0M
Karyopharm Therapeutics KPTI:US $ 6.68M 1.26M
Merk MRK:US $ 243M 34M
Novartis NOVN:VX 201M 5M
Novartis NVS:US $ 201M 5M
Pfizer PFE:US $ 322M 6M
Regeneron Pharmaceuticals REGN:US $ 13.6M 0.5M
Vertex Pharmaceuticals VRTX:US $ 14.9M 0.19M